Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan
With
Actelion
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of group 1 Pulmonary Atrial Hypertension (PAH) diagnosed during right heart catheterization (RHC) according to WHO criteria 28
WHO functional class II to III
Stable clinical condition, with no change in medical therapy for pulmonary arterial hypertension (PAH) for at least 3 months before enrollment
Planned follow-up at University of Michigan Hospital Centers over at least 1 year
If enrolled in clinical trial, must be in open-label extension stage on stable medications for at least 3 months.
Competent to give informed consent
Have computer and internet access
You may not be if
Life expectancy under 1 year
Co-morbidities which limit physical activity to a severe degree (i.e., permanently wheelchair bound, musculoskeletal disorders, recent myocardial infarction, unstable arrhythmia)
Current substance abuse, and/or a severe psychiatric disorder (including severe depression, psychosis, or dementia) which limits the patient's ability to follow the study protocol
Recently completed (\<6 months), current enrollment or planned enrollment in pulmonary rehab.
≥30 minutes of exercise, ≥ 1 day per week for the previous 3 months
Six-minute walk distance \<150 meters or \>550 meters
Moderate or severe obstructive lung disease forced expiratory volume/forced vital capacity (FEV1/FVC) \< 70% and FEV1 \< 65% of predicted value after bronchodilator administration).
Moderate or severe restrictive lung disease (total lung capacity \< 60% predicted value).
Arterial oxygen saturation (SpO2) \<88% during 6-minute walk test on baseline home oxygen prescription if applicable or SpO2 \<80% if uncorrected shunt.
History of exercise-induced syncope or arrhythmias.